scanX
Alembic Pharmaceuticals

Alembic Pharmaceuticals

938.60
+5.20
(0.56%)
ann
There are new updates from the company1 day ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
Market Cap
18,347.20 Cr
EPS
29.68
PE Ratio
30.66
Dividend Yield
1.17 %
Industry
Healthcare
52 Week High
1,197.70
52 Week Low
725.20
PB Ratio
3.55
Debt to Equity
0.18
Sector
Pharmaceuticals
Analyst Rating and Forecast
- By Refinitiv from12 analysts
HOLD
Analysts have suggested that investors can hold this stock
Buy
Buy+41.67 %
+41.67 %
Hold
Hold+50.00 %
+50.00 %
Sell
Sell+8.33 %
+8.33 %
Forecast For
Actual

Company News

View All News
Caret
positive
Alembic Pharmaceuticals Receives USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension1 day ago
Alembic Pharmaceuticals Limited received final approval from the US Food & Drug Administration for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL in both single-dose and multiple-dose vial formats. The approved product is therapeutically equivalent to Bristol-Myers Squibb Company's reference drug Kenalog-40 Injectable Suspension. The medication is indicated for various autoimmune, inflammatory, and other conditions where oral therapy is not feasible. The drug has an estimated market size of US$ 96 million for twelve months ending June 2025 according to IQVIA. With this approval, Alembic now has a cumulative total of 227 ANDA approvals from USFDA, comprising 206 final approvals and 21 tentative approvals.
positive
Alembic Pharmaceuticals Receives USFDA Approval for Paroxetine Extended-Release TabletsSep 25, 2025
Alembic Pharmaceuticals received final USFDA approval for Paroxetine Extended-Release Tablets in 25 MG and 37.5 MG strengths, which are equivalent to Paxil CR. With this approval, the company's total USFDA ANDA approvals have reached 226.
neutral
Alembic Pharmaceuticals Receives US FDA Establishment Inspection Report for Panelav API FacilitiesSep 13, 2025
Alembic Pharmaceuticals Limited has received an Establishment Inspection Report (EIR) from the US FDA for its API-I and API-II facility in Panelav. The inspection was conducted from May 26 to May 31, 2025. The company informed BSE and NSE about receiving the EIR report on September 13, 2025.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,679.10
#1 3,98,049.70
38.75
#1 54,729.00
9.71
#1 10,980
-19.84
61.71
Divis Laboratories
6,621.50
1,75,222.50
76.19
9,712.00
18.67
2,191
26.74
72.60
Cipla
1,577.60
1,26,768.90
23.67
28,409.50
7.12
5,291
9.88
60.63
Torrent Pharmaceuticals
3,584.30
1,19,599.80
60.49
11,539.40
6.99
1,911
19.91
53.74
Dr Reddys Laboratories
1,255.90
1,03,508.80
#1 18.25
33,741.20
16.73
5,725
1.26
48.97
Mankind Pharma
2,476.60
1,01,344.60
53.48
12,744.20
#1 20.90
2,007
-18.14
47.04
Zydus Life Science
987.65
99,073.80
21.09
23,511.00
18.55
4,615
2.60
45.37
Lupin
1,940.00
89,121.90
23.79
22,909.50
13.74
3,306
#1 51.64
46.82
Alkem Laboratories
5,581.50
66,047.70
28.61
13,458.30
3.70
2,216
21.39
63.11
Aurobindo Pharma
1,101.00
64,254.10
19.04
32,345.60
9.43
3,484
-10.24
50.87

Automatic Screeners on ScanX

Community
Resistance 1 Breached
Growth Rate
Revenue Growth
7.32 %
Net Income Growth
-5.49 %
Cash Flow Change
-89.05 %
ROE
-12.21 %
ROCE
6.31 %
EBITDA Margin (Avg.)
1.82 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
504
582
1,003
918
630
737
880
777
742
648
797
840
854
863
1,129
1,022
930
952
1,241
1,210
1,243
1,342
1,460
1,317
1,306
1,328
1,313
1,291
1,426
1,263
1,475
1,510
1,407
1,498
1,605
1,634
1,521
1,564
1,678
1,703
1,784
1,717
Expenses
405
478
629
532
484
580
702
632
606
547
610
653
680
712
825
776
749
757
895
884
926
934
1,014
949
960
1,090
1,054
1,030
1,268
1,255
1,244
1,274
1,203
1,288
1,387
1,364
1,257
1,325
1,409
1,433
1,498
1,430
EBITDA
99
103
375
386
146
158
178
146
136
102
187
188
174
151
305
246
181
195
346
326
318
408
447
368
346
238
259
261
158
9
231
236
205
210
218
269
263
239
270
270
286
287
Operating Profit %
19 %
18 %
37 %
42 %
23 %
21 %
20 %
19 %
18 %
16 %
23 %
22 %
20 %
18 %
27 %
24 %
19 %
20 %
28 %
27 %
23 %
30 %
30 %
28 %
25 %
18 %
18 %
19 %
10 %
1 %
16 %
16 %
14 %
13 %
13 %
16 %
17 %
15 %
15 %
15 %
15 %
16 %
Depreciation
11
13
13
22
24
19
21
21
22
22
26
26
32
28
29
29
30
35
36
42
44
42
44
47
51
53
55
56
123
67
68
67
74
66
68
69
70
69
71
70
69
74
Interest
0
1
1
1
2
1
1
1
2
1
0
1
1
2
6
6
5
5
7
7
8
7
5
2
3
2
5
4
7
9
12
15
14
14
16
15
11
13
19
22
25
24
Profit Before Tax
89
91
362
364
120
137
157
124
112
79
161
161
141
122
270
211
146
155
303
276
266
360
398
318
292
183
200
201
29
-67
151
155
116
130
135
185
183
157
180
178
192
190
Tax
18
19
73
95
29
33
37
37
19
12
39
30
47
32
70
42
23
36
52
49
62
66
73
33
49
24
36
29
7
-2
18
33
-36
9
-2
4
5
23
27
40
35
37
Net Profit
70
72
289
269
91
104
120
87
93
67
122
131
94
90
200
169
124
120
250
227
204
293
325
286
243
158
164
172
22
-66
133
122
153
121
137
180
178
135
153
138
157
154
EPS in ₹
3.73
3.72
15.30
14.26
4.82
5.50
6.36
4.59
4.94
3.54
6.45
6.93
4.98
4.80
10.61
9.01
6.58
6.56
13.06
12.42
11.93
15.99
17.24
14.88
12.75
8.37
8.34
8.74
1.11
-3.35
6.78
6.20
7.76
6.14
6.95
9.23
9.07
6.84
7.79
7.01
7.98
7.85
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
Fixed Assets
547
708
799
993
1,159
1,552
1,788
1,798
2,398
2,547
2,524
Current Assets
891
1,511
1,373
1,825
1,958
2,463
2,652
2,861
2,910
3,079
4,088
Capital Work in Progress
83
93
396
1,010
1,551
1,846
2,183
2,304
601
524
837
Investments
0
53
50
42
49
18
236
118
96
93
127
Other Assets
1,011
1,575
1,444
1,896
2,019
2,573
2,502
2,902
3,087
3,282
4,285
Total Liabilities
1,641
2,429
2,689
3,941
4,778
5,989
6,709
7,122
6,183
6,446
7,773
Current Liabilities
684
747
693
1,144
1,490
1,752
1,281
1,717
1,637
1,455
2,412
Non Current Liabilities
72
84
94
576
570
1,047
361
168
175
172
171
Total Equity
885
1,597
1,902
2,220
2,718
3,190
5,067
5,238
4,371
4,818
5,190
Reserve & Surplus
847
1,560
1,865
2,182
2,681
3,182
5,028
5,198
4,331
4,779
5,152
Share Capital
38
38
38
38
38
38
39
39
39
39
39
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
3
417
-286
-69
115
-127
26
-37
14
45
-37
Investing Activities
-256
-307
-486
-884
-756
-731
-840
-372
-448
-321
-568
Operating Activities
172
948
329
312
812
449
1,463
552
724
803
88
Financing Activities
87
-224
-129
503
59
155
-597
-217
-262
-438
444
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
69.48 %
69.48 %
69.48 %
69.48 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.61 %
69.67 %
69.67 %
69.74 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
4.52 %
4.46 %
4.32 %
3.94 %
4.17 %
3.94 %
3.96 %
4.05 %
DIIs
10.92 %
11.17 %
11.36 %
11.56 %
11.69 %
12.06 %
12.43 %
12.76 %
13.31 %
13.40 %
13.93 %
14.50 %
15.38 %
15.47 %
16.05 %
16.06 %
16.43 %
16.46 %
16.30 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
10.99 %
10.78 %
11.43 %
9.57 %
9.22 %
8.91 %
9.12 %
9.21 %
9.08 %
8.98 %
8.24 %
8.00 %
7.41 %
7.48 %
7.36 %
7.26 %
7.07 %
7.01 %
6.93 %
Others
8.61 %
8.57 %
7.73 %
9.39 %
9.47 %
9.41 %
8.84 %
8.42 %
8.00 %
8.01 %
8.22 %
3.37 %
3.14 %
3.13 %
3.04 %
2.90 %
2.88 %
2.89 %
2.99 %
No of Share Holders
0
0
99,809
1,01,686
1,23,059
1,10,038
1,06,437
1,01,457
1,03,811
97,607
89,552
85,212
76,567
74,829
91,429
93,944
91,336
89,013
89,969

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 4 4 5.5 10 14 10 8 11 11
Dividend Yield (%) 0.00 0.73 0.74 1.03 1.04 1.89 2.13 0.81 1.18 1.17

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
21 Jul 2021 DIVIDEND Dividend
₹ 14.00 /share
 19 Jul 2021 983.60 939.65
18 Aug 2022 DIVIDEND Dividend
₹ 10.00 /share
 17 Aug 2022 781.50 656.10
28 Jul 2023 DIVIDEND Dividend
₹ 8.00 /share
 28 Jul 2023 560.55 732.15
15 Jul 2024 DIVIDEND Dividend
₹ 11.00 /share
 15 Jul 2024 1,001.85 984.60
22 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 22 Jul 2024 845.20 1,079.55
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Nov 2024 1,182.75 1,139.20
03 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 03 Feb 2025 1,029.95 937.10
06 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 06 May 2025 849.90 905.45
29 Jul 2025 DIVIDEND Dividend
₹ 11.00 /share
 29 Jul 2025 905.45 1,000.40
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Aug 2025 1,031.40 967.25
05 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 05 Aug 2025 982.70 967.25

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 06, 2025
Intimation For Change Of Email Address Of The Registrar And Share Transfer Agent (RTA) Of The CompanyOct 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 30, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 15, 2025
Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its API - I & API - II Facility Located At Panelav.Sep 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 09, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 19, 2025
Intimation Of One On One Investor MeetAug 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 15, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations 2015") - Appointment Of Statutory Auditors And Secretarial AuditorsAug 05, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sAug 05, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 05, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2025
Updated Contact Details Of Key Managerial Personnel / Senior Officials Pursuant To Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 05, 2025
Unaudited Financial Results For The Qtr Ended 30Th June 2025.Aug 05, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 26, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 21, 2025
Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter Ended 30Th June 2025Jul 21, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 07, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 07, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 04, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 03, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 02, 2025
Volume MovementJul 01, 2025
Clarification sought from Alembic Pharmaceuticals LtdJul 01, 2025
Alembic Pharmaceuticals Receives USFDA Final Approval For Doxorubicin Hydrochloride Liposome InjectionJun 29, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 25, 2025
Alembic Pharmaceuticals Limited Has Received Establishment Inspection Report (EIR) For Its API-III Facility At KarakhadiJun 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 18, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Jun 17, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
DSP Midcap Direct Plan-Growth
1.20%
-410136
-0.26%
-0.30%
Edelweiss Mid Cap Direct Plan-Growth
0.00%
-337384
-0.28%
-0.30%
ICICI Prudential Children's Fund Direct-Growth
0.98%
150000
0.98%
0.98%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
1.70%
103262
0.07%
-0.02%
HDFC Multi Cap Fund Direct - Growth
0.00%
-92985
-0.05%
-0.05%
ICICI Prudential Smallcap Fund Direct Plan-Growth
0.50%
60110
0.05%
0.03%
Tata Nifty MidSmall Healthcare Index Fund Direct - Growth
0.00%
-14825
-0.89%
-0.88%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
1.40%
14071
0.19%
0.30%
Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct-Growth
0.00%
-2700
-0.88%
-0.89%
Bajaj Finserv Small Cap Fund Direct-Growth
0.35%
-2608
-0.06%
-0.10%
Bajaj Finserv Multi Cap Fund Direct-Growth
0.54%
-2392
-0.09%
-0.14%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.25%
-1445
-0.03%
-0.03%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.25%
-1025
-0.03%
-0.03%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.26%
948
-0.02%
0.26%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.25%
-685
-0.03%
-0.03%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.25%
-492
-0.03%
-0.03%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.25%
414
-0.03%
-0.03%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.25%
-313
-0.03%
-0.03%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.20%
298
0.00%
0.00%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.06%
-170
-0.01%
-0.01%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.25%
-155
-0.03%
-0.03%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.03%
65
0.00%
0.00%
SBI Nifty 500 Index Fund Direct-Growth
0.03%
-64
0.00%
0.00%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.25%
-39
-0.03%
-0.03%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.38%
-22
-0.01%
-0.02%

Technical Indicators

RSI(14)
Neutral
52.09
ATR(14)
Less Volatile
22.89
STOCH(9,6)
Neutral
63.11
STOCH RSI(14)
Neutral
73.10
MACD(12,26)
Bullish
3.12
ADX(14)
Weak Trend
14.95
UO(9)
Bearish
45.23
ROC(12)
Uptrend And Accelerating
4.13
WillR(14)
Neutral
-20.42
Bearish
3
Neutral
4
Bullish
2

About Alembic Pharmaceuticals

Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across chronic segments, including Dermatology, Anti-Infective, Cardiology, and Anti-Diabetic therapies. The company has manufacturing facilities in Gujarat and Sikkim, with research and development centers in Vadodara, Hyderabad, and New Jersey. Alembic has expanded its operations through acquisitions, joint ventures, and international subsidiaries, focusing on developing and marketing generic drugs in various global markets.
Website
https://www.alembicpharmaceuticals.com/
Chairperson NameChirayu R Amin
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Intraday Screeners
Fundamental Screeners
Price & Volume Screeners
Candlestick Screeners
Technical Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104